Growth PsA Market will Mainly be Driven by the Launch of Five New Pipeline Agents

| By | Biosimilars, Pharma market

The psoriatic arthritis (PsA) market was valued at $4.7bn in 2018 across the seven major markets (7MM*), and it is expected to grow to $9.3bn by 2028 at a compound annual growth rate (CAGR) of 7.0% according to GlobalData, a leading data and analytics company.

According to the company’s latest report, ‘Psoriatic Arthritis: Global Drug Forecast and Market Analysis to 2028’, growth will mainly be driven by the launch of five new pipeline agents (which include injectable anti-interleukins and oral Janus Kinase [JAK] inhibitors) as well as increasing prevalence, diagnostic, and treatment rates.

SunPharma’s Ilumya/Ilumetri (tildrakizumab) and UCB’s bimekizumab join a large roster of injectable anti-interleukins, which includes such members as J&J’s Stelara (ustekinumab), Novartis’ Cosentyx (secukinumab), and Eli Lilly’s Taltz (ixekizumab). This growing class is set to challenge the branded TNF-inhibitors, the current standard of care. Combined with existing therapies, anti-interleukins are expected to earn $4.1bn in 2028 and capture 60.9% of global PsA sales.

Oral JAK inhibitors also represent a rapidly growing drug treatment class; AbbVie’s Rinvoq (upadacitinib), Gilead/Galapagos’ filgotinib, and Pfizer’s brepocitinib tosylate will join Pfizer’s Xeljanz (tofacitinib), the only JAK inhibitor currently available for PsA. The JAK inhibitor class is expected to grow to $261.0m by 2028.

Tiffany Chan, Immunology Analyst at GlobalData, explains:

A major barrier for growth in the psoriatic arthritis market will be the emerging use of biosimilars and generics for some of the key marketed products, namely AbbVie’s Humira (adalimumab) and Xeljanz. Due to price differentials, biosimilars and generics are expected to take a portion of their branded counterparts’ market share and to temper the growth of the PsA market overall.

*7MM = US, France, Germany, Italy, Spain, UK and Japan.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.